Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.1 (
adenylate cyclase
)
19,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The chapter is focused on the mechanism of action of metabotropic P2Y nucleotide receptors: P2Y
1
, P2Y
2
, P2Y
12
, P2Y
14
and the ionotropic
P2X
7
receptor in glioma C6 cells. P2Y
1
and P2Y
12
both respond to ADP, but while P2Y
1
links to PLC and elevates cytosolic Ca
2+
concentration, P2Y
12
negatively couples to
adenylate cyclase
, maintaining cAMP at low level. In glioma C6, these two P2Y receptors modulate activities of ERK1/2 and PI3K/Akt signaling and the effects depend on physiological conditions of the cells. During prolonged serum deprivation, cell growth is arrested, the expression of the P2Y
1
receptor strongly decreases and P2Y
12
becomes a major player responsible for ADP-evoked signal transduction. The P2Y
12
receptor activates ERK1/2 kinase phosphorylation (a known cell proliferation regulator) and stimulates Akt activity, contributing to glioma invasiveness. In contrast, P2Y
1
has an inhibitory effect on Akt pathway signaling. Furthermore, the
P2X
7
receptor, often responsible for apoptotic fate, is not involved in Ca
2+
elevation in C6 cells. The shift in nucleotide receptor expression from P2Y
1
to P2Y
12
during serum withdrawal, the cross talk between both receptors and the lack of
P2X
7
activity shows the precise self-regulating mechanism, enhancing survival and preserving the neoplastic features of C6 cells.
...
PMID:Cross-Talk in Nucleotide Signaling in Glioma C6 Cells. 3203 8
<< Previous
1
2
3
